These results demonstrate that pretreatment of bone tissues isolated from both male and female patients, with three different types of aromatase inhibitors, reduces the capacity of culture supernatants to promote ER+ breast cancer cell proliferation in a dose-dependent manner. Here, CYP19A1 is linked to breast cancer.